Eli Lilly and Company

Washington University

Other

Kelly R Bales

Steven Marc Paul

David Michael Holtzman

Ronald DeMattos

Maximiliano Vasquez

Naoya Tsurushita

David J Cummins

Henry U Bryant

Barbara Cordell

Qiang Xu

Ronald Bradley Demattos

Asha Naidu

Mary Patricia Knadler

David M Holtzman

Steven M Paul

A diagnostic test for preclinical and clinical Alzheimer's disease is based on plasma levels of A&#x3b2;, A&#x3b2;, their ratio, or their rate of entry following administration of antibodies that sequester A&#x3b2;. Alterations of any of these parameters from control values identifies preclinical or clinical Alzheimer's disease.

Assay method for Alzheimer's disease

A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A&#x3b2; peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13-28 of the amyloid beta peptide A&#x3b2;.

Humanized antibodies that sequester amyloid beta peptide

Assay method for alzheimer's disease

A method to treat conditions characterized by formation of amyloid plaques both prophylactically and therapeutically is described. The method employs humanized antibodies which sequester soluble A&#x3b2; peptide from human biological fluids or which preferably specifically bind an epitope contained within position 13&#x2013;28 of the amyloid beta peptide A&#x3b2;.

Humanized antibodies that sequester abeta peptide

The present invention provides a method of assaying for and arresting, preventing and/or reversing the impairment of central and peripheral nervous system function comprising reducing &bgr;-amyloid plaque burden by the administration of compounds that reduce apoE expression. The compounds used in the method of the invention may be: 1) inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase; 2) inhibitors of cholesterol biosynthesis; 3) inhibitors of protein isoprenylation, specifically geranylgeranylation; and/or 4) inhibitors of NF-&kgr;B activation or function. Assays for compounds with inhibit apoE expression from microglial cells are also disclosed.

Assay to identify compounds that alter apolipoprotein E expression

The present invention provides a method of treating depression, mood swings, or Alzheimer's disease in a patient in need of such treatment by administering a selective estrogen receptor modulating compound of the formula ##STR1## in which R.sup.1 and R.sup.2 are independently hydroxy and alkoxy of one to four carbon atoms; and R.sup.3 and R.sup.4 are independently methyl or ethyl, or R.sup.3 and R.sup.4, taken together with the nitrogen atom to which they are attached, form a pyrrolidino, methyl-pyrrolidino, dimethylpyrrolidino, piperidino, morpholino, or hexamethyleneimino ring.

Treatment of central nervous system disorders with selective estrogen

Growing community of inventors

Coatsville, IN, United States of America

Kelly R Bales